Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules

Pharmaceutical Technology


Meisssner Launches New Website

Meissner Filtration Products (Camarillo, CA) recently launched its new website, http://www.meissner.com/. The new site highlights Meissner's line of laboratory products, including its "STyLUX" and "SteriLUX" 25-mm syringe filters and "Ultradyne" and "Steridyne" 50-mm vent filters. The site also describes Meissner's full-scale production elements such as "UltraCap" high-capacity capsules and "EverLUX" filter cartridges. The website allows users to access and download product literature easily. In addition, users can take a virtual manufacturing facility tour through a streaming video link.

ARx Opens Pharmaceutical Manufacturing Facility

ARx (Glen Rock, PA) officially opened its new pharmaceutical manufacturing facility 18 months after breaking ground. The 25,000-ft2 facility is designed to manufacture dissolvable film, transdermal, and buccal drug delivery systems for over-the-counter, prescription, and biopharmaceutical products. The globally-compliant facility triples ARx's manufacturing capacity and laboratory space.

ARx currently supports commercial thin-film products sold in the United States, Canada, and Latin America, including Novartis Consumer Health's "Triaminic" pediatric and infant cough and cold products, "Theraflu" cold and flu products, and "Gas-X" antigas relief products. The current facility increases the company's potential strip output to more than 1.4 billion strips per year.

ARx is a wholly owned subsidiary of Adhesives Research (Glen Rock, PA).


ADVERTISEMENT

RELATED CONTENT
Pharma Capsules
Pharma Capsules
Pharma Capsules
Pharma Capsules
Pharma Capsules
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here